Zenlabs Ethica Ltd
₹ 40.5
-0.71%
22 Nov
- close price
About
Incorporated in 1993, Zenlabs Ethica Ltd is engaged in trading, marketing and distribution of pharmaceutical formulations.
Key Points
- Market Cap ₹ 26.4 Cr.
- Current Price ₹ 40.5
- High / Low ₹ 70.0 / 36.0
- Stock P/E 75.3
- Book Value ₹ 15.8
- Dividend Yield 0.00 %
- ROCE 7.01 %
- ROE 4.24 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.57 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -2.18% over past five years.
- Company has a low return on equity of 7.40% over last 3 years.
- Promoter holding has decreased over last 3 years: -14.6%
- Working capital days have increased from 75.1 days to 130 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 15.09 | 78.73 | 69.85 | 65.37 | 58.50 | 56.64 | 69.09 | 66.89 | 58.56 | 56.64 | |
| 0.15 | 0.04 | 0.05 | 14.89 | 77.28 | 68.00 | 63.28 | 59.20 | 54.89 | 66.70 | 63.98 | 56.15 | 53.95 | |
| Operating Profit | -0.15 | -0.04 | -0.05 | 0.20 | 1.45 | 1.85 | 2.09 | -0.70 | 1.75 | 2.39 | 2.91 | 2.41 | 2.69 |
| OPM % | 1.33% | 1.84% | 2.65% | 3.20% | -1.20% | 3.09% | 3.46% | 4.35% | 4.12% | 4.75% | |||
| 0.10 | 0.00 | 0.00 | -0.03 | 0.08 | 0.10 | 0.10 | 0.05 | 0.11 | 0.09 | -0.45 | 0.30 | 0.02 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.02 | 0.10 | 0.09 | 0.07 | 0.23 | 0.29 | 0.37 | 0.53 | 0.83 | 0.93 |
| Depreciation | 0.02 | 0.01 | 0.01 | 0.06 | 0.20 | 0.20 | 0.23 | 0.29 | 0.71 | 0.89 | 1.25 | 1.29 | 1.28 |
| Profit before tax | -0.07 | -0.05 | -0.06 | 0.09 | 1.23 | 1.66 | 1.89 | -1.17 | 0.86 | 1.22 | 0.68 | 0.59 | 0.50 |
| Tax % | 0.00% | 0.00% | 16.67% | -88.89% | 21.95% | 29.52% | 32.80% | -36.75% | 10.47% | 36.07% | 26.47% | 27.12% | |
| -0.07 | -0.06 | -0.07 | 0.17 | 0.95 | 1.16 | 1.26 | -0.73 | 0.77 | 0.78 | 0.49 | 0.42 | 0.35 | |
| EPS in Rs | -0.18 | -0.16 | -0.18 | 0.26 | 1.46 | 1.78 | 1.94 | -1.12 | 1.18 | 1.20 | 0.75 | 0.65 | 0.54 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 16.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 33.21% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | 1% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | -20% |
| 3 Years: | -19% |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | -2% |
| 3 Years: | 7% |
| 1 Year: | -10% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 5% |
| 3 Years: | 7% |
| Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.62 | 3.62 | 3.62 | 6.20 | 6.20 | 6.20 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 |
| Reserves | -1.51 | -1.57 | -1.65 | -1.41 | -0.41 | 0.81 | 1.77 | 0.90 | 2.05 | 2.82 | 3.19 | 3.61 | 3.75 |
| 0.00 | 0.00 | 0.00 | 1.09 | 0.96 | 0.85 | 0.60 | 0.73 | 2.60 | 3.90 | 5.85 | 14.86 | 11.34 | |
| 1.75 | 1.75 | 1.77 | 24.49 | 26.62 | 21.96 | 26.01 | 25.85 | 21.04 | 24.66 | 27.95 | 15.28 | 18.87 | |
| Total Liabilities | 3.86 | 3.80 | 3.74 | 30.37 | 33.37 | 29.82 | 34.89 | 33.99 | 32.20 | 37.89 | 43.50 | 40.26 | 40.47 |
| 0.10 | 0.09 | 0.06 | 1.68 | 1.50 | 1.33 | 1.36 | 1.12 | 3.51 | 3.53 | 5.03 | 3.70 | 2.90 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 1.25 | 0.95 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 |
| 3.76 | 3.71 | 3.68 | 27.44 | 30.92 | 27.79 | 32.83 | 32.17 | 27.99 | 33.66 | 37.77 | 35.86 | 36.87 | |
| Total Assets | 3.86 | 3.80 | 3.74 | 30.37 | 33.37 | 29.82 | 34.89 | 33.99 | 32.20 | 37.89 | 43.50 | 40.26 | 40.47 |
Cash Flows
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | -0.01 | 0.02 | 0.92 | -1.06 | 0.36 | 0.80 | 0.45 | -8.41 | -0.38 | 1.52 | -9.06 | |
| 0.00 | 0.00 | 0.00 | -1.69 | -0.02 | -0.03 | -0.22 | 0.01 | 0.15 | 0.00 | -1.47 | 0.11 | |
| 0.00 | 0.00 | 0.00 | 3.23 | -0.27 | -0.23 | -0.14 | -0.03 | -0.52 | 0.31 | 0.06 | 8.24 | |
| Net Cash Flow | 0.00 | -0.01 | 0.02 | 2.47 | -1.35 | 0.09 | 0.44 | 0.43 | -8.78 | -0.07 | 0.11 | -0.71 |
Ratios
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 398.14 | 107.65 | 126.40 | 139.37 | 138.76 | 121.67 | 109.57 | 118.41 | 129.21 | |||
| Inventory Days | 249.62 | 34.42 | 11.12 | 31.23 | 33.95 | 40.46 | 56.05 | 77.85 | 100.05 | |||
| Days Payable | 665.46 | 136.41 | 125.88 | 161.27 | 165.31 | 150.28 | 141.30 | 174.04 | 101.21 | |||
| Cash Conversion Cycle | -17.70 | 5.66 | 11.64 | 9.33 | 7.40 | 11.85 | 24.32 | 22.21 | 128.04 | |||
| Working Capital Days | 4.84 | 13.95 | 23.36 | 28.42 | 24.02 | 32.48 | 44.96 | 50.31 | 129.96 | |||
| ROCE % | -3.27% | -2.40% | -2.99% | 9.94% | 21.06% | 23.96% | 24.13% | -11.05% | 12.02% | 13.04% | 12.44% | 7.01% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Nov - Submission of Newspaper Advertisement for the publication of extract of Un-audited financial results for the Quarter and Half year ended September 30, 2024.
-
Non-Applicability Of Disclosure Of Related Party Transactions For The Half Year Ended On 30Th September, 2024
12 Nov - Non-applicability of related party transaction disclosure.
-
Un-Audited Financial Results For The Quarter And Half Year Ended On 30Th September, 2024.
12 Nov - Approval of unaudited financial results for Q2 2024.
-
Board Meeting Outcome for Board Meeting Outcome For Approval Of Un-Audited Financial Results For Quarter And Half Year Ended On 30Th September, 2024
12 Nov - Approval of unaudited financial results for Q2 2024.
-
Board Meeting Intimation for Approval Of Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended 30Th September, 2024.
7 Nov - Board meeting to approve Q2 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
Zenlabs Ethica Ltd is a WHO-GMP certified, third party manufacturing pharma company. Company was launched in collaboration with Zenlabs Pharmaceutical Inc, Canada. It is a part of Preet Remedies Group which has five manufacturing units namely Preet Remedies Pvt. Ltd., Oasis Pharma & Phytomolecules Pvt. Ltd., Quixotic Healthcare Unit I & II, and Alpha Products. At any of these facilities, minimum order quantity offered is 2000 boxes of drugs.